On April 19, 2016, the Health Resources and Services Administration (HRSA) is publishing a notice reopening for 30 days the comment period on its June 17, 2015 proposed rule entitled “340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation.”  While comments may be submitted on any aspect of the proposed rule, feedback is specifically solicited on the following issues:  the ceiling price for a covered outpatient drug exception and alternatives to the “penny pricing” proposal; the methodology for calculating new drug prices; and whether the “knowing and intentional” standard should be further defined.   The new comment deadline is May 19, 2016.